 Albert Moraska
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Massage | 7 | 2018 | 42 | 2.770 |
Why?
| | Trigger Points | 5 | 2023 | 14 | 2.600 |
Why?
| | Myofascial Pain Syndromes | 3 | 2023 | 13 | 1.850 |
Why?
| | Tension-Type Headache | 3 | 2018 | 6 | 1.690 |
Why?
| | Lactic Acid | 3 | 2018 | 275 | 0.930 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.620 |
Why?
| | Regional Blood Flow | 1 | 2018 | 424 | 0.540 |
Why?
| | Pain Threshold | 4 | 2018 | 67 | 0.510 |
Why?
| | Glucose | 2 | 2018 | 897 | 0.500 |
Why?
| | Acupressure | 1 | 2012 | 4 | 0.420 |
Why?
| | Headache | 1 | 2012 | 133 | 0.380 |
Why?
| | Pain Measurement | 4 | 2017 | 444 | 0.380 |
Why?
| | Muscle Fatigue | 2 | 2007 | 94 | 0.310 |
Why?
| | Pinch Strength | 1 | 2008 | 1 | 0.310 |
Why?
| | Superficial Back Muscles | 2 | 2018 | 13 | 0.300 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2008 | 27 | 0.300 |
Why?
| | Hand Strength | 1 | 2008 | 96 | 0.290 |
Why?
| | Hand | 1 | 2008 | 134 | 0.280 |
Why?
| | Running | 2 | 2007 | 207 | 0.270 |
Why?
| | Range of Motion, Articular | 1 | 2008 | 350 | 0.260 |
Why?
| | Musculoskeletal Manipulations | 1 | 2005 | 11 | 0.250 |
Why?
| | Low Back Pain | 1 | 2007 | 95 | 0.250 |
Why?
| | Muscle, Skeletal | 3 | 2017 | 1473 | 0.240 |
Why?
| | Leg | 1 | 2007 | 225 | 0.240 |
Why?
| | Coxsackievirus Infections | 6 | 1993 | 12 | 0.240 |
Why?
| | Waiting Lists | 2 | 2017 | 211 | 0.230 |
Why?
| | Physical Fitness | 1 | 2005 | 179 | 0.230 |
Why?
| | Sports Medicine | 1 | 2005 | 104 | 0.220 |
Why?
| | Sports | 1 | 2005 | 187 | 0.210 |
Why?
| | Physical Exertion | 2 | 2001 | 209 | 0.210 |
Why?
| | Immune Tolerance | 2 | 2001 | 323 | 0.200 |
Why?
| | Myocarditis | 5 | 1994 | 93 | 0.200 |
Why?
| | Doxorubicin | 3 | 1993 | 285 | 0.190 |
Why?
| | Treatment Outcome | 4 | 2018 | 9088 | 0.190 |
Why?
| | Physical Conditioning, Animal | 2 | 2000 | 194 | 0.190 |
Why?
| | Enterovirus B, Human | 7 | 1994 | 24 | 0.180 |
Why?
| | Rats, Sprague-Dawley | 3 | 2001 | 2218 | 0.170 |
Why?
| | Extracellular Fluid | 1 | 2018 | 30 | 0.150 |
Why?
| | Adult | 6 | 2018 | 30550 | 0.150 |
Why?
| | Occipital Lobe | 1 | 2017 | 23 | 0.150 |
Why?
| | Adaptation, Physiological | 1 | 2000 | 483 | 0.140 |
Why?
| | Single-Blind Method | 1 | 2017 | 258 | 0.140 |
Why?
| | Male | 14 | 2018 | 55599 | 0.140 |
Why?
| | Pressure | 1 | 2017 | 214 | 0.130 |
Why?
| | Isometric Contraction | 1 | 2017 | 156 | 0.130 |
Why?
| | Pilot Projects | 2 | 2012 | 1373 | 0.130 |
Why?
| | Mice, Inbred BALB C | 7 | 1993 | 1144 | 0.130 |
Why?
| | Humans | 10 | 2023 | 114689 | 0.120 |
Why?
| | Medical Records | 1 | 2015 | 153 | 0.110 |
Why?
| | Female | 7 | 2018 | 59511 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2001 | 944 | 0.110 |
Why?
| | T-Lymphocytes | 4 | 1993 | 1737 | 0.110 |
Why?
| | Depression | 1 | 2001 | 1134 | 0.110 |
Why?
| | Myocardium | 4 | 1999 | 913 | 0.100 |
Why?
| | Young Adult | 2 | 2018 | 10470 | 0.100 |
Why?
| | Microdialysis | 1 | 2012 | 49 | 0.100 |
Why?
| | Lactates | 1 | 2012 | 79 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1992 | 154 | 0.100 |
Why?
| | Hemocyanins | 2 | 2001 | 55 | 0.090 |
Why?
| | Immunity | 1 | 1992 | 121 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 696 | 0.090 |
Why?
| | Autoimmune Diseases | 1 | 1993 | 382 | 0.090 |
Why?
| | Antibodies | 1 | 1992 | 371 | 0.080 |
Why?
| | Immunoglobulin M | 2 | 2001 | 246 | 0.080 |
Why?
| | Pain Management | 1 | 2012 | 288 | 0.080 |
Why?
| | Middle Aged | 3 | 2018 | 26737 | 0.080 |
Why?
| | Research | 1 | 2011 | 394 | 0.070 |
Why?
| | Heat-Shock Proteins | 2 | 1999 | 113 | 0.060 |
Why?
| | Heart | 4 | 1992 | 612 | 0.060 |
Why?
| | Rats | 3 | 2001 | 4958 | 0.060 |
Why?
| | Quality of Life | 1 | 2015 | 2353 | 0.060 |
Why?
| | Citrate (si)-Synthase | 2 | 2000 | 46 | 0.050 |
Why?
| | Antigens, Viral | 2 | 1993 | 176 | 0.050 |
Why?
| | Transcortin | 1 | 2000 | 14 | 0.050 |
Why?
| | Exercise | 1 | 2011 | 1644 | 0.050 |
Why?
| | Electric Stimulation | 1 | 2001 | 250 | 0.040 |
Why?
| | Nitrites | 1 | 2000 | 75 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 66 | 0.040 |
Why?
| | Adolescent | 1 | 2018 | 17848 | 0.040 |
Why?
| | Animals | 11 | 2001 | 31706 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2001 | 206 | 0.040 |
Why?
| | Body Weight | 2 | 2001 | 869 | 0.040 |
Why?
| | Thymus Gland | 1 | 2000 | 296 | 0.040 |
Why?
| | Antibody Formation | 1 | 2000 | 266 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 743 | 0.040 |
Why?
| | Lymphocyte Activation | 2 | 2000 | 1037 | 0.040 |
Why?
| | Lymphocytes | 1 | 2000 | 330 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2001 | 770 | 0.040 |
Why?
| | Weight Gain | 1 | 2000 | 453 | 0.040 |
Why?
| | Streptococcus pyogenes | 2 | 1994 | 30 | 0.040 |
Why?
| | Colorado | 1 | 2007 | 4099 | 0.040 |
Why?
| | Cross Reactions | 2 | 1993 | 117 | 0.030 |
Why?
| | Autoimmunity | 2 | 1993 | 813 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 1993 | 195 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2007 | 4623 | 0.030 |
Why?
| | Mice | 8 | 1994 | 14869 | 0.030 |
Why?
| | Motor Activity | 1 | 1999 | 640 | 0.030 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 1994 | 58 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 1994 | 112 | 0.030 |
Why?
| | Antibodies, Monoclonal | 4 | 1994 | 1262 | 0.030 |
Why?
| | Spleen | 2 | 1992 | 487 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 1992 | 797 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1992 | 97 | 0.030 |
Why?
| | CD8 Antigens | 1 | 1992 | 69 | 0.020 |
Why?
| | Hot Temperature | 1 | 1993 | 302 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1992 | 198 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1991 | 53 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1992 | 397 | 0.020 |
Why?
| | Epitopes | 1 | 1993 | 435 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1994 | 695 | 0.020 |
Why?
| | Genetic Variation | 2 | 1991 | 870 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1991 | 383 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 1992 | 380 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1994 | 736 | 0.020 |
Why?
| | Cells, Cultured | 2 | 1992 | 3886 | 0.020 |
Why?
| | Animals, Newborn | 3 | 1992 | 778 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 1994 | 1982 | 0.010 |
Why?
| | Mitochondria, Heart | 1 | 1999 | 73 | 0.010 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 2785 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 318 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1147 | 0.010 |
Why?
| | Heart Rate | 1 | 1999 | 709 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 1994 | 396 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 1994 | 217 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 1993 | 49 | 0.010 |
Why?
| | Freund's Adjuvant | 1 | 1992 | 17 | 0.010 |
Why?
| | Lymphocyte Depletion | 1 | 1992 | 116 | 0.010 |
Why?
| | Virulence | 1 | 1992 | 227 | 0.010 |
Why?
| | Cell Separation | 1 | 1992 | 291 | 0.010 |
Why?
| | CD4 Antigens | 1 | 1991 | 123 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 217 | 0.010 |
Why?
| | Uridine | 1 | 1991 | 29 | 0.010 |
Why?
| | Viral Proteins | 1 | 1993 | 281 | 0.010 |
Why?
| | Leucine | 1 | 1991 | 102 | 0.010 |
Why?
| | Immunotherapy, Adoptive | 1 | 1991 | 184 | 0.010 |
Why?
| | HeLa Cells | 1 | 1991 | 562 | 0.010 |
Why?
| | Peptides | 1 | 1994 | 848 | 0.000 |
Why?
| | Virus Replication | 1 | 1991 | 395 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1991 | 520 | 0.000 |
Why?
| | Kinetics | 1 | 1991 | 1551 | 0.000 |
Why?
| | B-Lymphocytes | 1 | 1991 | 766 | 0.000 |
Why?
|
|
Moraska's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|